RECENT NEWS

The Government has announced it is to roll out a new system of league tables for England’s NHS Trusts, as it aims to deliver better patient care following what it says is record investment.

A new report has shown that the UK can build a more preventive, efficient, and resilient healthcare system fit for the future by prioritising investment in in vitro diagnostics (IVDs) across the NHS.

Aiforia Technologies, a provider of deep learning AI solutions for digital pathology, has announced a strategic partnership with healthcare firm Siemens Healthineers, which aims to expand the availability of Aiforia’s AI-driven solutions across European diagnostic laboratories.

Proscia has announced the launch of Proscia Aperture, a pioneering precision medicine solution that automatically identifies candidates at the moment of diagnosis - addressing one of healthcare’s most critical challenges.

Tickets are now available for ‘The Power to Disrupt Through Diagnostics’ the next POCT Innovators one-day conference, which takes place Monday 15 December at London’s National Army Museum.

The Royal College of Pathologists (RCPath) has collaborated with The Royal College of Radiologists and other Medical Royal Colleges and associations to call for reform of multidisciplinary team meetings.

Aiforia Technologies has launched a new CE-IVD marked clinical AI solution for lymph node metastasis detection.

Radiometer, urgent and acute care testing specialist, will unite with Leica Biosystems and Cepheid at IBMS Congress 2025 to spotlight the breadth and scale of the Danaher Diagnostics portfolio.

Beckman Coulter Life Sciences is advancing nucleic acid quantification through a strategic collaboration with Hombrechtikon Systems Engineering, a Swiss provider of customised automation and engineering solutions for the life sciences and diagnostics sectors.

Dartford and Gravesham NHS Trust has taken a significant step towards a more digital future by rolling out electronic test ordering for pathology and radiology using Clinisys ICE.

Diagnostic technology firm Randox Laboratories has announced plans to expand its US site in Jefferson County, West Virginia, from a 48-person sales and distribution operation into a full-scale production laboratory, further increasing the company’s 4.1 billion annually manufactured tests.

Newly published data show that nearly 1 in 5 children starting primary school are not fully protected against several serious diseases, prompting the UK Health Security Agency (UKHSA) and NHS England to call for parents and healthcare workers to catch up on missed vaccinations.

Cherwell (an AnalytiChem company) has announced the retirement of Andy Whittard, Managing Director, and the appointment of Stuart Hall, Cherwell’s current Director of Finance, as his successor.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved gepotidacin (Blujepa), a new kind of oral antibiotic pill to treat uncomplicated urinary tract infections (UTIs) in females.

Cancer patients will benefit from the potential for faster diagnosis and better access to specialist opinions, following the go-live of a digital pathology solution across five NHS sites in Devon and Cornwall.

Evident has announced a definitive agreement to acquire Pramana, a leading manufacturer of digital pathology solutions.

A new programme to evaluate how wastewater monitoring could be used to detect a wider range of dangerous pathogens has been launched by the UK Health Security Agency (UKHSA).

Antibiotic susceptibility testing (AST) technology firm Avails Medical has announced that it has signed its first US commercial customer, a world renowned academic medical centre and flagship hospital for a six-hospital system, for the company's eQUANT system.

Tempus AI, a technology company leading the adoption of AI to advance precision medicine, has announced the acquisition of Paige, an AI company specialising in digital pathology.

While it has long been known that gut microbiota plays a role in the development of colorectal cancer, translating these findings into clinical practice has proven challenging. This is because different strains of the same bacterial species can have opposite effects, with some promoting the disease and others having no effect.